Literature DB >> 23557875

Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression.

Valerio Leoni1, Jeffrey D Long, James A Mills, Stefano Di Donato, Jane S Paulsen.   

Abstract

24S-hydroxycholesterol (24OHC) is involved in the conversion of excess cholesterol in the brain, and its level in plasma is related to the number of metabolically active neuronal cells. Previous research suggests that plasma 24OHC is substantially reduced in the presence of neurodegenerative disease. Huntington disease (HD) is an inherited autosomal dominant neurodegenerative disorder caused by a cytosine-adenine-guanine (CAG) triplet repeat expansion in the coding region of the huntingtin (HTT) gene. The current study focused on the relative importance of 24OHC as a marker of HD progression. Using mass spectrometry methods, we examined plasma 24OHC levels in three groups of gene-expanded individuals (Low, Medium, High) characterized by their progression at entry into the parent PREDICT-HD study, along with a group of non-gene-expanded controls (total N=150). In addition, the correlation of 24OHC with a number of motor, cognitive, and imagining markers was examined, and effect sizes for group differences among the markers were computed for comparison with 24OHC. Results show a progression gradient as 24OHC levels decreased as the progression group increased (Low to High). The effect size of group differences for 24OHC was larger than all the other variables, except striatal volume. 24OHC was significantly correlated with many of the other key variables. The results are interpreted in terms of cholesterol synthesis and neuronal degeneration. This study provides evidence that 24OHC is a relatively important marker of HD progression.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23557875      PMCID: PMC3671851          DOI: 10.1016/j.nbd.2013.03.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  47 in total

Review 1.  CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches.

Authors:  Douglas R Langbehn; Michael R Hayden; Jane S Paulsen
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

2.  Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease.

Authors:  Alina Solomon; Valerio Leoni; Miia Kivipelto; Ariadna Besga; Anne Rita Oksengård; Per Julin; Leif Svensson; Lars-Olof Wahlund; Niels Andreasen; Bengt Winblad; Hilkka Soininen; Ingemar Björkhem
Journal:  Neurosci Lett       Date:  2009-06-26       Impact factor: 3.046

3.  Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes.

Authors:  Marta Valenza; Valerio Leoni; Joanna M Karasinska; Lara Petricca; Jianjia Fan; Jeffrey Carroll; Mahmoud A Pouladi; Elisa Fossale; Huu Phuc Nguyen; Olaf Riess; Marcy MacDonald; Cheryl Wellington; Stefano DiDonato; Michael Hayden; Elena Cattaneo
Journal:  J Neurosci       Date:  2010-08-11       Impact factor: 6.167

4.  Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.

Authors:  N Z Hobbs; J Barnes; C Frost; S M D Henley; E J Wild; K Macdonald; R A Barker; R I Scahill; N C Fox; S J Tabrizi
Journal:  AJNR Am J Neuroradiol       Date:  2010-02-11       Impact factor: 3.825

5.  Self-paced timing detects and tracks change in prodromal Huntington disease.

Authors:  Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Kevin Duff; Leigh J Beglinger; Chiachi Wang; Justin J F O'Rourke; Julie C Stout; David J Moser
Journal:  Neuropsychology       Date:  2010-07       Impact factor: 3.295

6.  Fully automated analysis using BRAINS: AutoWorkup.

Authors:  Ronald Pierson; Hans Johnson; Gregory Harris; Helen Keefe; Jane S Paulsen; Nancy C Andreasen; Vincent A Magnotta
Journal:  Neuroimage       Date:  2010-06-25       Impact factor: 6.556

7.  Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease.

Authors:  Valerio Leoni; Caterina Mariotti; Sarah J Tabrizi; Marta Valenza; Edward J Wild; Susie M D Henley; Nicola Z Hobbs; Maria Luisa Mandelli; Marina Grisoli; Ingemar Björkhem; Elena Cattaneo; Stefano Di Donato
Journal:  Brain       Date:  2008-09-04       Impact factor: 13.501

8.  Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.

Authors:  Susie M D Henley; Edward J Wild; Nicola Z Hobbs; Chris Frost; David G MacManus; Roger A Barker; Nick C Fox; Sarah J Tabrizi
Journal:  Mov Disord       Date:  2009-04-30       Impact factor: 10.338

Review 9.  Oxysterols and neurodegenerative diseases.

Authors:  Ingemar Björkhem; Angel Cedazo-Minguez; Valerio Leoni; Steve Meaney
Journal:  Mol Aspects Med       Date:  2009-02-25

10.  Detection of Huntington's disease decades before diagnosis: the Predict-HD study.

Authors:  J S Paulsen; D R Langbehn; J C Stout; E Aylward; C A Ross; M Nance; M Guttman; S Johnson; M MacDonald; L J Beglinger; K Duff; E Kayson; K Biglan; I Shoulson; D Oakes; M Hayden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12-20       Impact factor: 10.154

View more
  20 in total

Review 1.  24(S)-Hydroxycholesterol as a Modulator of Neuronal Signaling and Survival.

Authors:  Min-Yu Sun; Andrew J Linsenbardt; Christine M Emnett; Lawrence N Eisenman; Yukitoshi Izumi; Charles F Zorumski; Steve Mennerick
Journal:  Neuroscientist       Date:  2015-01-27       Impact factor: 7.519

Review 2.  HDL and cognition in neurodegenerative disorders.

Authors:  David A Hottman; Dustin Chernick; Shaowu Cheng; Zhe Wang; Ling Li
Journal:  Neurobiol Dis       Date:  2014-08-13       Impact factor: 5.996

Review 3.  Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Authors:  Alexey M Petrov; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

4.  Assessment of cholesterol homeostasis in the living human brain.

Authors:  Ahmed Haider; Chunyu Zhao; Lu Wang; Zhiwei Xiao; Jian Rong; Xiaotian Xia; Zhen Chen; Stefanie K Pfister; Natalia Mast; Eylan Yutuc; Jiahui Chen; Yinlong Li; Tuo Shao; Geoffrey I Warnock; Alyaa Dawoud; Theresa R Connors; Derek H Oakley; Huiyi Wei; Jinghao Wang; Zhihua Zheng; Hao Xu; April T Davenport; James B Daunais; Richard S Van; Yihan Shao; Yuqin Wang; Ming-Rong Zhang; Catherine Gebhard; Irina Pikuleva; Allan I Levey; William J Griffiths; Steven H Liang
Journal:  Sci Transl Med       Date:  2022-10-05       Impact factor: 19.319

Review 5.  Metabolism in Huntington's disease: a major contributor to pathology.

Authors:  Akanksha Singh; Namita Agrawal
Journal:  Metab Brain Dis       Date:  2021-10-27       Impact factor: 3.655

Review 6.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

Review 7.  Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications.

Authors:  Irina A Pikuleva; Nathalie Cartier
Journal:  Front Aging Neurosci       Date:  2021-07-08       Impact factor: 5.750

Review 8.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

9.  CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.

Authors:  Lydie Boussicault; Sandro Alves; Antonin Lamazière; Anabelle Planques; Nicolas Heck; Lara Moumné; Gaëtan Despres; Susanne Bolte; Amélie Hu; Christiane Pagès; Laurie Galvan; Francoise Piguet; Patrick Aubourg; Nathalie Cartier; Jocelyne Caboche; Sandrine Betuing
Journal:  Brain       Date:  2016-01-29       Impact factor: 13.501

10.  Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease.

Authors:  M Valenza; M Marullo; E Di Paolo; E Cesana; C Zuccato; G Biella; E Cattaneo
Journal:  Cell Death Differ       Date:  2014-10-10       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.